Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Tramadol is FDA-approved for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The extended-release formulation is approved for around-the-clock management of chronic pain in opioid-tolerant adults.

• Acute moderate to moderately severe pain — post-operative pain, injury-related pain, dental pain
• Chronic pain — osteoarthritis, low back pain, fibromyalgia (off-label), neuropathic pain conditions
• Cancer pain — mild to moderate cancer-related pain, particularly when non-opioid options have failed
• Neuropathic pain (off-label) — diabetic neuropathy, post-herpetic neuralgia; the serotonin/norepinephrine component contributes to neuropathic pain relief beyond pure opioid mechanisms

How It Works

Tramadol is unique among analgesics because it has two distinct pharmacological mechanisms operating simultaneously, each contributing to pain relief through different pathways.

Mechanism 1 — Opioid receptor agonism: Tramadol and its active metabolite O-desmethyltramadol (O-DMTS, also called M1) bind to mu-opioid receptors in the brain and spinal cord. Mu-receptor activation inhibits ascending pain signals and activates descending pain inhibitory pathways. The M1 metabolite is approximately 200 times more potent at the mu-opioid receptor than the parent drug and is primarily responsible for the opioid-like pain relief — and for the opioid-like risks of dependence and respiratory depression.

Mechanism 2 — Monoamine reuptake inhibition: Tramadol also inhibits the reuptake of serotonin and norepinephrine (similar to SNRIs like duloxetine and venlafaxine). Increased serotonin and norepinephrine in the spinal cord enhance the descending inhibitory pain pathways that naturally suppress pain signal transmission.

Side Effects

Common

• Nausea and vomiting (the most frequently reported side effect)
• Dizziness and vertigo
• Constipation
• Drowsiness and fatigue
• Headache
• Dry mouth
• Sweating
• Itching (pruritus)

Serious

• Respiratory depression — risk increases with high doses, co-administration of CNS depressants, or in ultra-rapid CYP2D6 metabolizers; can be fatal
• Seizures — tramadol lowers the seizure threshold; seizure risk is elevated at higher amounts, with history of epilepsy, and when combined with other seizure threshold-lowering drugs (SSRIs, TCAs, antipsychotics)
• Serotonin syndrome — potentially life-threatening; risk is significant with concurrent use of SSRIs, SNRIs, MAOIs, trazodone, tricyclics, triptans, or other serotonergic drugs
• Physical dependence and addiction — tramadol is a Schedule IV controlled substance with real addiction potential; withdrawal syndrome resembles both opioid and antidepressant withdrawal
• Hypoglycemia — rare but reported, particularly in elderly patients
• Suicidality — cases of overdose or intentional overdose have been reported; caution in patients with depression

Drug Interactions

Drug / Class	Interaction	Clinical Significance
MAOIs (phenelzine, tranylcypromine, linezolid, methylene blue)	Severe, potentially fatal serotonin syndrome and seizures; absolute contraindication	High — contraindicated; 14-day washout required after MAOI
SSRIs / SNRIs (fluoxetine, sertraline, duloxetine)	Additive serotonergic risk (serotonin syndrome); additionally, CYP2D6 inhibiting SSRIs (fluoxetine, paroxetine) block conversion of tramadol to active M1 metabolite, reducing efficacy AND raising parent drug seizure risk	High — use with caution; monitor closely for both serotonin toxicity and altered analgesic response
CNS depressants (opioids, benzodiazepines, alcohol, muscle relaxants, sleep aids)	Additive CNS and respiratory depression; combination with other opioids or benzodiazepines significantly increases overdose and death risk	High — FDA black box warning; avoid or use extreme caution
CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine)	Block conversion to active M1 metabolite, reducing pain relief but potentially raising seizure risk from elevated parent tramadol levels	Moderate to high — analgesic effect may be unpredictable
Carbamazepine	CYP3A4 inducer that significantly reduces tramadol blood levels, reducing pain relief; also lowers seizure threshold (opposing effect)	Moderate — avoid combination or use alternative analgesic
Warfarin	Tramadol may potentiate warfarin's anticoagulant effect, increasing bleeding risk	Moderate — monitor INR closely
Triptans (sumatriptan, rizatriptan)	Additive serotonin agonism increases serotonin syndrome risk	Moderate — use with caution; monitor for serotonin toxicity symptoms

Warnings & Contraindications

• Children under 12: Contraindicated for pain management after tonsillectomy/adenoidectomy and in children under 12 due to ultra-rapid metabolizer risk of fatal respiratory depression.
• Adolescents (12–18) who are obese or have obstructive sleep apnea: Contraindicated for post-tonsillectomy pain in this population due to heightened respiratory depression risk.
• Epilepsy: Tramadol lowers the seizure threshold. Use with caution in patients with seizure disorders or those taking medications that lower seizure threshold.
• Renal and hepatic impairment: Tramadol and its metabolites accumulate with reduced kidney or liver function; may require extended dosing intervals or dose reduction — consult a provider.
• Opioid reversal: Naloxone can reverse tramadol's respiratory depression but does not reverse serotonin syndrome components and may precipitate seizures.

FAQ

Is tramadol a "weak" opioid that is safer than other opioids?

This is a dangerous misconception. While tramadol was initially marketed as having lower addiction potential than traditional opioids, the DEA scheduled it as a controlled substance in 2014 after recognizing its significant abuse potential. Tramadol causes physical dependence, carries real addiction risk, and can cause fatal respiratory depression — particularly in ultra-rapid CYP2D6 metabolizers or when combined with other CNS depressants. Its dual mechanism also creates unique risks (serotonin syndrome, seizures) not seen with traditional opioids.

What does tramadol withdrawal feel like?

Tramadol withdrawal is particularly challenging because it has two components: a traditional opioid withdrawal syndrome (anxiety, restlessness, muscle aches, sweating, nausea, diarrhea) AND an antidepressant-like discontinuation syndrome (electric shock sensations/"brain zaps," mood changes, perceptual disturbances, agitation). This dual withdrawal is more complex and often more distressing than withdrawal from traditional opioids. Medical supervision is strongly recommended for tapering off tramadol after chronic use.

Can tramadol cause seizures even at normal amounts?

Yes. Tramadol has been associated with seizures even within the prescribed range, though the risk increases substantially at higher amounts and with overdose. Risk factors for tramadol-related seizures include history of epilepsy, concurrent use of drugs that lower the seizure threshold (SSRIs, TCAs, antipsychotics, bupropion), withdrawal from CNS depressants, and genetic ultra-rapid metabolism. Patients with epilepsy or seizure history should generally avoid tramadol.

Why does tramadol interact with so many antidepressants?

Because tramadol itself inhibits serotonin and norepinephrine reuptake — the same mechanism as SNRIs — combining it with SSRIs, SNRIs, MAOIs, or other serotonergic medications creates additive or synergistic serotonin activity. Excess serotonin causes serotonin syndrome, which ranges from mild (tremor, agitation) to severe (hyperthermia, rhabdomyolysis, seizures, coma, death). Additionally, several common SSRIs (fluoxetine, paroxetine) inhibit the CYP2D6 enzyme that activates tramadol, making the drug unpredictably less effective or triggering more seizures from elevated parent drug levels.

→ Opioid Side Effects Guide → Chronic Pain Medications Guide